SL4903
/ SenlangBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 15, 2026
In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms
(clinicaltrials.gov)
- P1 | N=18 | Not yet recruiting | Sponsor: Liping Dou
New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology • Plasmacytoma • GPRC5D
1 to 1
Of
1
Go to page
1